title: Mantle cell lymphoma: evolving novel options.
abstract: Mantle cell lymphoma (MCL) represents only 6% of non-Hodgkin's lymphoma but is one of the most active fields of clinical investigation. Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense chemotherapy with hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and rituximab. Unfortunately, no standard therapy has been defined, and most patients eventually relapse. An impressive number of novel agents are currently being tested, the bulk of which are biologic agents or targeted therapies. Bortezomib is the first in class of proteasome inhibitors and the first new agent to be approved in relapsed/refractory MCL. Other small molecules have shown encouraging activity, including mTOR and Bcl-2 inhibitors, novel antibodies, and new cytotoxic agents. Future trials will also benefit from new molecular approaches through pharmacogenomics.
authors: Lymphoma Division, Hackensack Medical University Cancer Center, 20 Prospect Avenue, Hackensack, NJ 07601, USA. agoy@humed.com
authors: Andre
authors: A
authors: Goy
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D016499:Radioimmunotherapy
references: J Clin Oncol. 2003 May 1;21(9):1740-5
references: 12735303
references: J Clin Oncol. 2007 May 1;25(13):1741-6
references: 17389337
references: Blood. 2007 May 15;109(10):4441-9
references: 17227835
references: Oncology (Williston Park). 1998 Oct;12(10 Suppl 8):49-55
references: 9830633
references: J Clin Oncol. 2006 Jan 1;24(1):166-73
references: 16330674
references: Blood. 2003 Oct 15;102(8):3003-9
references: 12842981
references: Leuk Lymphoma. 2001 Sep-Oct;42(5):1015-22
references: 11697618
references: Blood. 2006 Mar 15;107(6):2271-8
references: 16332971
references: Blood. 2004 Aug 1;104(3):795-801
references: 15090459
references: J Clin Oncol. 2006 Jul 1;24(19):3113-20
references: 16754936
references: J Clin Oncol. 2005 Aug 10;23(23):5347-56
references: 15983389
references: Blood. 2002 May 1;99(9):3158-62
references: 11964278
references: Clin Cancer Res. 2006 Sep 1;12(17):5165-73
references: 16951235
references: J Clin Oncol. 2002 Mar 1;20(5):1288-94
references: 11870171
references: Mod Pathol. 2001 Nov;14(11):1133-40
references: 11706075
references: Blood. 2006 Apr 15;107(8):3407
references: 16597597
references: J Clin Oncol. 1998 Feb;16(2):579-83
references: 9469344
references: Blood. 2004 Oct 15;104(8):2269-71
references: 15166030
references: Nat Med. 2005 Sep;11(9):986-91
references: 16116429
references: Nat Rev Cancer. 2004 May;4(5):349-60
references: 15122206
references: Cancer Cell. 2003 Feb;3(2):185-97
references: 12620412
references: J Clin Oncol. 2005 Feb 1;23(4):667-75
references: 15613697
references: Ann Hematol. 2007 Feb;86(2):101-5
references: 17089127
references: J Clin Oncol. 2005 Feb 1;23(4):676-84
references: 15613699
references: Blood. 2007 Jan 15;109(2):399-404
references: 17003373
references: J Clin Oncol. 2005 Oct 1;23(28):7013-23
references: 16145068
references: J Clin Oncol. 2005 May 20;23(15):3383-9
references: 15908650
references: J Clin Oncol. 2003 Dec 1;21(23):4407-12
references: 14645431
references: Blood. 2005 Dec 15;106(13):4315-21
references: 16123218
references: Blood. 2004 Nov 15;104(10):3064-71
references: 15284112
references: Curr Opin Immunol. 2006 Apr;18(2):206-13
references: 16464564
references: Blood. 2006 Sep 1;108(5):1668-76
references: 16645163
references: Leukemia. 2002 Apr;16(4):587-93
references: 11960337
references: Blood. 2008 Jan 15;111(2):558-65
references: 17962512
references: Leukemia. 2007 Mar;21(3):524-8
references: 17268531
references: Br J Haematol. 2006 Aug;134(4):391-8
references: 16882131
references: J Clin Oncol. 2005 Sep 10;23(26):6364-9
references: 16155021
references: J Clin Oncol. 2006 Oct 20;24(30):4867-74
references: 17001068
references: J Immunol. 2003 Jul 1;171(1):88-95
references: 12816986
references: Eur J Haematol. 2006 Jan;76(1):42-50
references: 16343270
references: Cancer. 2003 Feb 1;97(3):586-91
references: 12548600
references: Cancer Res. 2003 Oct 1;63(19):6174-7
references: 14559800
references: J Clin Oncol. 1998 Dec;16(12):3803-9
references: 9850025